Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Allergan, Brent Saunders
AbbVie's Allergan buyout depends on Botox growth. Will it last?
Tuesday, August 6, 2019
U.S. Botox growth in the product's wrinkle indication slowed in the second quarter, just as Evolus launched rival Jeuveau.
Is this the end for Allergan's Restasis tribal licensing deal?
Monday, April 15, 2019
Allergan took its tribal licensing deal all the way to the Supreme Court, which declined to hear the case.
Top 10 drugs losing exclusivity in 2019
Pharma companies do their best to fight off patent expirations and generic competition as long as possible to protect their big moneymakers. But this year looks like the end of the line for many of the industry's top brands.
Allergan nixes women's health sale in wake of Esmya rejection
Tuesday, January 29, 2019
Allergan had said back in May that it would pursue a sale of its women's health business, but at least for now, the company plans to keep the unit.
Allergan, Mohawk tribe ask SCOTUS to review Restasis deal
Wednesday, January 16, 2019
Can tribal immunity shield a drug—in this case, Restasis—from a patent challenge? Allergan and the Mohawk tribe want the Supreme Court to weigh in.
Allergan nixes Texas plant expansion as Restasis generics loom
Monday, November 5, 2018
With generics expected soon for eye drug Restasis, Allergan has canceled a $200 million expansion at its Waco, Texas, manufacturing plant.
Allergan's maligned strategy is fine, CEO says, citing Q2 beat
Thursday, July 26, 2018
Forget the critics and activists, Allergan CEO Brent Saunders said Thursday after releasing better-than-expected Q2 numbers.
Court rejects Allergan's tribal licensing strategy
Monday, July 23, 2018
An appeals court rejected Allergan's attempt to protect Restasis patents with sovereign immunity, clearing the way for generics.